key: cord-1001599-yzn4ue9q
authors: Fong, Dominic; Mair, Maximilian J.; Mitterer, Manfred
title: High levels of anti-SARS-CoV-2 IgG antibodies in previously infected cancer patients after a single dose of BNT 162b2 vaccine
date: 2021-06-11
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.05.036
sha: fe9c1bbafd07e2ce22d058dccef8131b837babf5
doc_id: 1001599
cord_uid: yzn4ue9q

nan

As patients with cancer constitute a vulnerable population at higher risk of contracting severe COVID-19, they represent a priority group for SARS-CoV-2 vaccination. However, despite favouring these patients theoretically, cancer patients were excluded from major registration trials on SARS-CoV-2 vaccines [1] . Furthermore, two recent reports on the immunogenicity of mRNA vaccines in cancer patients excluded those from the study having previous SARS-CoV-2 exposure [2, 3] . We compared IgG antibody levels after one or two doses of BNT162b2 (Pfizer-BioNTech) vaccine in cancer patients with or without prior SARS-CoV-2 infection.

All patients with an RT-PCR confirmed (N=74) or serologically detected (N=15) SARS-CoV-2 infection (CoV+) who underwent vaccination with BNT162b2 (Pfizer-BioNTech) between 05/03/2021 and 07/05/2021 at the outpatient department of the "Franz Tappeiner" Hospital Merano were included in this retrospective study. In addition, a control group including 154 consecutive cancer patients without documented preexisting SARS-CoV-2 immunity (CoV-) was analyzed. After a median time of 24 days (range 10-68) after infection, CoV+ patients underwent baseline blood testing for detection of IgG antibodies against the nucleocapsid (N)protein and to the receptor-binding domain of the S1 subunit of the spike (S)-protein of SARS-CoV-2. In CoV-patients N/S-protein was measured on the same day of administration the first vaccine dose. At week three after the first vaccine dose, all patients repeated blood tests to quantitatively assess S-IgG antibody levels. Serum anti-N/S IgG were detected using the Abbot SARS-CoV-2 IgG chemiluminiscent microparticle immunoassay (CMIA), according to the manufacturer's instructions. The results were expressed as arbitrary units (AU) per milliliter and S-IgG values of >50 AU were interpreted as seropositive (upper limit: 40000 AU/mL). CoV+ patients who were still seronegative for S-IgG after the first vaccine dose received a second dose, whereas all CoV-patients were fully vaccinated with two doses. 

Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)

Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)

Association de Recherche sur les Cancers Gynécologiques-Groupes d'Investigateurs Nationaux pour l'étude des

Fédération Francophone de Cancérologie Digestive (FFCD)

Groupe d'Oncologie Radiothérapie Tête et Cou-Intergroupe ORL

InterGroupe Coopérateur de Neuro-Oncologie/Association des Neuro-Oncologues d'Expression Française (IGCNO-ANOCEF)

Société Française de Chirurgie Digestive (SFCD)

Société Française d'Endoscopie Digestive (SFED)

Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)

Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 JAMA